The 57% CRR vs <5% historical benchmark is a strong efficacy signal that could expand NBTXR3's addressable market beyond HNSCC into the large NSCLC indication. However, n=7 is too small for definitive conclusions. Watch for Part 2 expansion data and the ongoing Phase 3 NANORAY-312 readout in HNSCC as the next major catalysts. The J&J partnership provides financial and development support, reducing execution risk.
Price Chart
Executive Summary
Nanobiotix announced Part 1 data from the Johnson & Johnson-sponsored Phase 2 CONVERGE study of NBTXR3 (JNJ-1900) in stage 3 inoperable NSCLC at ESTRO 2026. In 7 evaluable patients, the overall response rate was 85.7% with a 57.1% complete response rate and 100% disease control rate, versus a historical complete response rate of <5% with standard of care. This is a highly promising early efficacy signal for a large addressable indication, though the sample size is very small and the data are preliminary.
Key Facts
- Part 1 data from J&J-sponsored Phase 2 CONVERGE study of NBTXR3 in stage 3 inoperable NSCLC presented at ESTRO 2026
- ORR of 85.7% (6/7 patients) and CRR of 57.1% (4/7 patients) in patients receiving full treatment regimen
- Disease control rate of 100% (7/7 patients) with no progressive disease observed
- Historical standard of care complete response rate is <5% (per Antonia et al. 2017)
- NBTXR3 is a first-in-class hafnium oxide nanoparticle radioenhancer administered via intratumoral injection
- The program is led by NANORAY-312, a global Phase 3 study in head and neck cancer
- NBTXR3 has FDA Fast Track designation for HNSCC and is partnered with Johnson & Johnson via a 2023 license agreement
Financial Impact
No financial data provided in the press release. The data are early-stage (n=7) and not yet registrational. Potential TAM for stage 3 NSCLC is large, but no revenue projections or deal milestones were disclosed.
Risk Factors
- Very small sample size (n=7) — efficacy rates are likely to decline in larger cohorts
- Part 1 data only; Part 2 expansion and randomized data are needed to confirm signal
- NSCLC is a competitive landscape with multiple approved IO/chemo combinations
- No timeline provided for Part 2 data or registrational path in NSCLC
- NBTXR3 requires intratumoral injection, which may limit adoption versus systemic therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296239 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+20 | — | — |
Oct 20, 2026 6d ago | 6-K | $25.83 | awaiting T+20 | — | $31.53 (+22.07%) |
Oct 1, 2026 25d ago | 6-K | $25.75 | awaiting T+20 | — | $31.53 (+22.45%) |
Oct 1, 2026 25d ago | Press Release | $25.75 | awaiting T+20 | — | $31.53 (+22.45%) |
Sep 24, 2026 4w ago | 6-K | $33.31 $29.36 | ▲ +11.86% | ▲ +10.38% | $31.53 (+5.34%) |
Sep 24, 2026 4w ago | 6-K | $33.31 $29.36 | ▼ −11.86% | ▼ −10.38% | $31.53 (−5.34%) |
Sep 24, 2026 4w ago | Press Release | $33.31 $29.36 | ▼ −11.86% | ▼ −10.38% | $31.53 (−5.34%) |
Sep 22, 2026 4w ago | Press Release | $35.24 $25.83 | ▼ −26.70% | ▼ −27.39% | $31.53 (−10.53%) |
Sep 14, 2026 6w ago | 6-K | $35.73 $23.40 | ▼ −34.51% | ▼ −36.77% | $31.53 (−11.75%) |
Jul 31, 2026 12w ago | 6-K | $38.89 $40.64 | ▲ +4.50% | ▲ +3.26% | $31.53 (−18.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers